Denali Therapeutics (DNLI) Shares Outstanding (Weighted Average) (2017 - 2025)
Historic Shares Outstanding (Weighted Average) for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $172.4 million.
- Denali Therapeutics' Shares Outstanding (Weighted Average) rose 174.94% to $172.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.4 million, marking a year-over-year increase of 174.94%. This contributed to the annual value of $164.5 million for FY2024, which is 1972.97% up from last year.
- Latest data reveals that Denali Therapeutics reported Shares Outstanding (Weighted Average) of $172.4 million as of Q3 2025, which was up 174.94% from $171.4 million recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Shares Outstanding (Weighted Average) peaked at $172.4 million during Q3 2025, and registered a low of $120.9 million during Q1 2021.
- Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $137.0 million (2023), whereas its average is $141.9 million.
- In the last 5 years, Denali Therapeutics' Shares Outstanding (Weighted Average) soared by 141.57% in 2022 and then soared by 2319.21% in 2024.
- Quarter analysis of 5 years shows Denali Therapeutics' Shares Outstanding (Weighted Average) stood at $121.5 million in 2021, then rose by 3.3% to $125.5 million in 2022, then rose by 9.43% to $137.4 million in 2023, then grew by 19.73% to $164.5 million in 2024, then increased by 4.83% to $172.4 million in 2025.
- Its Shares Outstanding (Weighted Average) stands at $172.4 million for Q3 2025, versus $171.4 million for Q2 2025 and $171.2 million for Q1 2025.